Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | DCTPP1 | Q9H773 | 4/20 | 0.44 |
| ▸ | SMO | Q99835 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11943415 | 0.92 | DRD2 (0.47) | MAPTALDH1A1DCTPP1SMODRD2 | |
| SCHEMBL11943338 | 0.87 | ALDH1A1 (0.51) | MAPTALDH1A1DCTPP1DRD2DRD4 | |
| SCHEMBL14080954 | 0.85 | ALDH1A1 (0.51) | MAPTALDH1A1DCTPP1SMODRD2 | |
| SCHEMBL11943428 | 0.85 | SMO (0.44) | MAPTTRPC5ALDH1A1SMODRD2 | |
| SCHEMBL11943406 | 0.84 | SMO (0.53) | MAPTTRPC5ALDH1A1DCTPP1SMO | |
| SCHEMBL11943401 | 0.84 | ALDH1A1 (0.47) | MAPTALDH1A1SMODRD2DRD4 | |
| SCHEMBL14082776 | 0.83 | MAPK14 (0.44) | MAPTALDH1A1DCTPP1SMODRD2 | |
| SCHEMBL11943425 | 0.82 | SMO (0.51) | MAPTTRPC5ALDH1A1DCTPP1SMO | |
| SCHEMBL11943417 | 0.82 | MAPK14 (0.42) | MAPTSMODRD2DRD4DRD3 | |
| SCHEMBL11943403 | 0.81 | ALDH1A1 (0.55) | MAPTALDH1A1DCTPP1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | DPM1, GMPS, MAN2A1 | MAPT 3651/4885TRPC5 4555/4885ALDH1A1 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.